Preferred Label : Alintegimod;
NCIt synonyms : Integrin Agonist 7HP349; Integrin Activator 7HP349;
NCIt definition : An orally bioavailable, allosteric, small molecule activator of integrin cell adhesion
receptors very late antigen-4 (VLA-4; integrin alpha4/beta1) and lymphocyte function-associated
antigen-1 (LFA-1; integrin alphaL/beta2), with potential immunomodulatory and antineoplastic
activities. Upon oral administration, alintegimod activates VLA-4 and LFA-1 expressed
on the surface of leukocytes, thereby promoting the VLA-4- and LFA-1-mediated adhesion
of leukocytes to counter-receptors vascular cell adhesion molecule-1 (VCAM-1) and
intercellular adhesion molecule 1 (ICAM-1). This may promote VLA-4/VCAM-1- and LFA-1/ICAM-1-mediated
cell-cell adhesion between naive T-cells and antigen presenting cells (APCs) and enhance
T-cell activation. The enhanced VCAM-1 and ICAM-1 binding by the activated integrins
expressed on activated T-cells may also promote intratumoral T-cell accumulation and
infiltration. This may lead to enhanced T-cell-mediated killing of tumor cells. Integrins
VLA-4 and LFA-1 are cellular adhesion molecules (CAMs) that play key roles in antigen
presentation and leukocyte migration.;
UNII : NX38VST3GU;
CAS number : 1378535-08-0;
Molecule name : 7HP 349; 7HP-349;
NCI Metathesaurus CUI : CL1647832;
Origin ID : C178334;
UMLS CUI : C5854864;
Semantic type(s)
- concept_is_in_subset
- has_target
